Q-omics provides the consensus-scored RXRG profile across patient tissues and cancer cell-line models. RXRG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RXRG is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, RXRG RNA expression shows 11,851 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, THCA, and TGCT as cancer lineages where RXRG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RXRG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RXRG survival associations across molecular data types. RXRG RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RXRG RNA expression–survival associations across cancer types. High RXRG expression shows unfavorable associations in KIRP and BLCA, but favorable associations in MESO, KIRC, THCA and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RXRG RNA expression.
This table summarizes RXRG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RXRG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RXRG shows lower tumor expression in BLCA, COAD, LUAD, LUSC and STAD and higher tumor expression in THCA. The THCA box plot shows higher RXRG RNA expression in tumor versus normal tissue (log2 FC = +5.181, t-test p < 0.001).
This table shows molecular features associated with RXRG in patient tissues and cancer cell lines. In patient samples, RXRG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RXRG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
